Lemaitre Vascular Inc. (LMAT) is an internationally recognized company in the development, manufacture, and distribution of medical devices used in the treatment of peripheral vascular disease. Founded in 1983 by surgeon George D. LeMaitre, the company's constant commitment to innovation and improvement has positioned it as a global leader in vascular surgery.
Lemaitre Vascular Inc. is publicly traded on the NASDAQ Global Market under the symbol LMAT. It is based in Burlington, Massachusetts, USA, with additional offices and distribution networks across North America, Europe, Asia, and Australia. This allows the company to service physicians, hospitals, and medical facilities throughout the world.
The company offers over 20 different types of medical devices, including the patented AlboGraft® Polyester Vascular Graft which is widely recognized for its superior resistance to aneurysm formation. Other innovative products range from embolectomy catheters, vascular grafts, valvulotomes, stent grafts, to carotid shunts and remote endarterectomy devices. The company also recently introduced the XenoSure® Biologic Patch to reduce bleeding in vascular surgery procedures.
Lemaitre Vascular Inc. is committed to the highest manufacturing and quality control standards, with manufacturing facilities in Massachusetts, California, Canada, and Italy that adhere strictly to the regulations of the U.S. Food & Drug Administration (FDA) and the European CE Mark.
Moreover, the company places a strong emphasis on maintaining close ties with the medical community. Through continuous dialogue with physicians and clinicians, Lemaitre Vascular Inc. can assess and respond swiftly to unmet clinical needs, driving the development and improvement of their products.
Despite its success, Lemaitre Vascular remains committed to the same passion and vision for innovation that it had as a small surgical start-up. This speaks volumes as to why Lemaitre Vascular Inc. is revered not only for its groundbreaking medical devices but also for its dedication in improving vascular care worldwide. With a continued emphasis on product refinement and development, the company is dedicated to fulfilling its mission of providing best-in-class vascular devices to surgeons and improving patient care.
In summary, Lemaitre Vascular Inc. exemplifies a successful medical device company that integrates continuous innovation, superior quality, and close interaction with the medical community, leading to improved treatment of peripheral vascular diseases and better outcomes for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $105.60 against its opening share price of $80.89. The company's third-quarter revenue increased by 11.3% year-over-year to $67.97 million, slightly exceeding estimates, but its EPS of $0.65 missed the consensus and was down from the previous year. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, translating to an annual dividend of $1.00 and a 1.2% yield.
Boston Trust Walden Corp has initiated a new position in LeMaitre Vascular (NASDAQ:LMAT), acquiring 345,634 shares valued at approximately $28.5 million. This investment comes as LeMaitre Vascular reported mixed third-quarter results, with revenue exceeding estimates but earnings per share falling short. The company also declared a quarterly dividend of $0.25 per share, and analysts currently hold an average "Hold" rating with a consensus price target of $105.60.
LeMaitre Vascular Inc. reported preliminary Q3 2026 sales of $68.0 million, an 11% increase year-over-year, with EPS of $0.65. The company also announced a $100 million share repurchase authorization, a $0.25 quarterly dividend, and the acquisition of certain vascular assets from B. Braun for $19.2 million. Despite increased operating expenses, management projects 2026 sales growth of 11% and EPS growth of 18%.
LeMaitre Vascular (NASDAQ: LMAT) reported Q3 2026 revenue of $67.97 million, surpassing Wall Street estimates, but its stock dropped 11.9% due to disappointing Q4 revenue guidance and a GAAP profit miss. Despite solid historical revenue and EPS growth, the company's full-year EPS outlook also fell short of analyst consensus, leading to a weaker quarter overall.
LeMaitre Vascular, Inc. reported strong Q3 2026 results with sales up 11% to $68.0 million and organic growth of 12%. The company announced a quarterly dividend of $0.25/share and provided optimistic guidance for Q4 and the full year 2026, driven by biologics and a recent acquisition. LeMaitre also detailed its financial performance, business outlook, and non-GAAP adjustments.
Bridge City Capital LLC significantly increased its stake in LeMaitre Vascular (NASDAQ:LMAT) by 35.5% in the third quarter, acquiring an additional 30,639 shares to hold a total of 116,980 shares valued at $9.66 million. Despite this institutional buying, the company's recent quarterly results missed analyst expectations for both earnings and revenue, leading to a weakened analyst sentiment and several downgrades. The consensus rating for LMAT is currently "Hold" with an average target price of $110.60.
This article analyzes Lemaitre Vascular Inc. (NASDAQ: LMAT), highlighting conflicting sentiment and a mid-channel oscillation pattern. AI models propose three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, indicating varying support and resistance levels.
LeMaitre Vascular (LMAT) is anticipated to release its Q3 2026 earnings after market close on Wednesday, November 4th, with analysts projecting earnings of $0.686 per share and $67.39 million in revenue. The company's previous quarter missed expectations with $0.74 EPS against an $0.81 estimate, and its revenue of $70.38 million was below the $71.47 million forecast. Investor sentiment remains cautious, with LMAT shares trading at $84.19 and analysts holding an average "Hold" rating with a $110.60 price target.